Publication Name	World Journal of Hepatology
Manuscript ID	33313
Country	United States

Received	2017-02-07 10:41
Peer-Review Started	2017-02-07 14:35
To Make the First Decision	2017-03-27 11:23
Return for Revision	2017-03-28 15:48
Revised	2017-04-06 07:58
Second Decision	2017-04-24 17:55
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2017-05-05 16:44
Articles in Press	2017-05-05 16:44
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-06-05 06:15
Publish the Manuscript Online	2017-07-05 04:40

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease
Manuscript Source	Invited Manuscript
All Author List	Marco Ladino, Fernando Pedraza and David Roth
Funding Agency and Grant Number
Corresponding Author	David Roth, MD, Katz Family Division of Nephrology and Hypertension, University of Miami, 1120 N.W. 14th Street, Room 813, Miami, FL 33136, United States. d.roth@med.miami.edu
Key Words	Hepatitis C virus; Chronic kidney disease; Direct acting antiviral agents; Kidney transplantation
Core Tip	Advances in the understanding of the molecular biology of hepatitis C virus (HCV) have ushered in a new era in treatment. Recent studies have shifted the focus to the more difficult-to-treat cohorts of patients. The presence of chronic kidney disease and end stage renal disease were exclusion criteria for the pivotal clinical direct-acting antiviral agents trials, creating a group of patients with a large unmet medical need. This review will update the reader on the use of the direct acting antiviral agents in the HCV-infected patient with kidney disease. Recommendations for the timing of therapy, choice of agents and management of the kidney transplant candidate will be presented.
Publish Date	2017-07-05 04:40
Citation	Ladino M, Pedraza F, Roth D. Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease. World J Hepatol 2017; 9(19): 833-839
URL	http://www.wjgnet.com/1948-5182/full/v9/i19/833.htm
DOI	http://dx.doi.org/10.4254/wjh.v9.i19.833

Full Article (PDF)	WJH-9-833.pdf
Full Article (Word)	WJH-9-833.doc
Manuscript File	33313-Review.docx
Answering Reviewers	33313-Answering reviewers.pdf
Audio Core Tip	33313-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	33313-Conflict-of-interest statement.pdf
Copyright License Agreement	33313-Copyright assignment.pdf
Peer-review Report	33313-Peer-review(s).pdf
Scientific Misconduct Check	33313-Scientific misconduct check.pdf
Scientific Editor Work List	33313-Scientific editor work list.pdf